

**In the Claims:**

Please amend the claims as shown. The listing of claims will replace all prior versions and listings of claims in the application.

Claims 1-93. Cancelled.

94. (Currently Amended) A method for regulating intraocular pressure by inhibiting sodium-hydrogen antiport activity in the eye of a human or animal subject in need of antiport regulation, the method comprising administering to ciliary epithelial cells of ~~an~~ the eye of ~~a human or an animal~~ the subject having a trabecular network, a pharmaceutical composition; ~~wherein the pharmaceutical composition comprises~~ comprising a pressure-modulating amount of at least one sodium-hydrogen exchange (NHE) inhibitor, and thereby inhibiting sodium-hydrogen antiport activity.

95. (Previously Presented) The method of claim 94, wherein the at least one sodium-hydrogen exchanger (NHE) inhibitor is a sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor.

96. (Currently Amended) The method of claim 94, wherein the NHE inhibitor is selected from the group consisting of an amiloride, ethyl-isopropyl-amiloride (EIPA), dimethylamiloride (DMA), HOE694, methylpropylamiloride, ~~a cariporide~~, and ~~analog~~ derivatives thereof.

97. (Previously Presented) The method of claim 94, wherein the pharmaceutical composition further comprises an inhibitor of a  $\text{Na}^+\text{-K}^+\text{-2Cl}^-$  symport.

98. (Previously Presented) The method of claim 97, wherein the  $\text{Na}^+\text{-K}^+\text{-2Cl}^-$  symport inhibitor is bumetanide.

99. (Previously Presented) The method of claim 94, wherein the pharmaceutical composition further comprises an anion exchanger isoform 2 (AE2).

100. (Previously Presented) The method of claim 99, wherein the inhibitor of anion exchanger isoform 2 is 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS).

101. (Previously Presented) The method of claim 94, wherein the pharmaceutical composition further comprises at least one compound selected from the group consisting of miotics, beta blockers, carbonic anhydrase inhibitors, and precursor prostaglandins.

102. (Previously Presented) The method of claim 94, wherein administration of the pharmaceutical composition is topical, intravitreal, via an ocular insert, or via an implanted reservoir.

103. (Currently Amended) The method of claim 94, wherein the human or animal ~~having a trabecular network~~ subject has glaucoma.

104. (Currently Amended) The method of claim 94, wherein the human or animal ~~having a trabecular network~~ subject is subject to glaucoma.

105. (Previously Presented) The method of claim 94, wherein the pharmaceutical composition consists essentially of a pressure-modulating amount of at least one sodium-hydrogen exchange inhibitor.

106. (Previously Presented) The method of claim 105, wherein the at least one sodium-hydrogen exchanger (NHE) inhibitor is a sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor.

107. (Currently Amended) The method of claim 105, wherein the NHE inhibitor is selected from the group consisting of an amiloride, ethyl-isopropyl-amiloride (EIPA), dimethylamiloride (DMA), HOE694, methylpropylamiloride, ~~a-cariperide~~, and ~~analog~~ derivatives thereof.

108. (Currently Amended) A method for regulating salt uptake or release by ciliary epithelial cells in an eye of a human or animal subject in need of regulating salt uptake or release in the cells, wherein said subject has ~~of a human eye or eye of an animal having~~ a trabecular network, the method comprising ~~by~~ controlling or modulating the function of one or more antiports of ~~aqueous humor ciliary epithelial by administering to~~ the ciliary epithelial cells of the aqueous humor by administering to the cells a modulating amount of a pharmaceutical composition consisting essentially of an NHE inhibitor, and thereby inhibiting salt uptake or release by the ciliary epithelial cells.

109. (Previously Presented) The method of claim 108, wherein the modulating effect is reversible upon cessation of administration of the NHE inhibitor.

110. (Previously Presented) The method of claim 108, wherein the pharmaceutical composition is administered to the cells *in vitro* or *in vivo*.

111. (Cancelled).

112. (Currently Amended) The method of claim 108, wherein the NHE inhibitor comprises amiloride or an amiloride analog derivative.
113. (Previously Presented) The method of claim 112, wherein the amiloride comprises either amiloride or ethyl-isopropyl-amiloride.
114. (Cancelled).
115. (Previously Presented) The method of claim 108, wherein an anion is transferred into the ciliary epithelial cells of the aqueous humor to block native chloride channels.
116. (Previously Presented) The method of claim 115, wherein the anion comprises cyclamate.